Ken Griffin Adverum Biotechnologies, Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$0.75 - $1.26 $11,400 - $19,152	-15,200 Reduced 96.82%	500 $0
Q3 2023 Nov 14, 2023	BUY	$1.5 - $2.33 $23,550 - $36,581	15,700 New	15,700 $23,000
Q1 2023 May 15, 2023	SELL	$0.62 - $0.85 $28,582 - $39,185	-46,100 Reduced 68.91%	20,800 $14,000
Q4 2022 Feb 14, 2023	BUY	$0.54 - $10.3 $16,308 - $311,060	30,200 Added 82.29%	66,900 $38,000
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $10,944 - $110,352	-11,400 Reduced 23.7%	36,700 $35,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.